Document Detail

A finding of highly selective synthetic inhibitor of plasma kallikrein; its action to bradykinin generation, intrinsic coagulation and experimental DIC.
MedLine Citation:
PMID:  1466271     Owner:  NLM     Status:  MEDLINE    
We found a novel and highly selective synthetic inhibitor of plasma kallikrein (PK), called PKSI-527; the Ki value was 0.81 microM. PKSI-527 inhibited the bradykinin (BK) generation induced by kaolin and prolonged partial thromboplastin time (PTT). PKSI-527 prevented the decrease of fibrinogen (Fg) levels due to i.v. injection of ellagic acid in mice and ameliorated the endotoxin (ET)-induced DIC in rats.
S Okamoto; K Wanaka; A Hijikata-Okunomiya; Y Okada; Y Katsuura
Publication Detail:
Type:  In Vitro; Journal Article    
Journal Detail:
Title:  Agents and actions. Supplements     Volume:  38 ( Pt 1)     ISSN:  0379-0363     ISO Abbreviation:  Agents Actions Suppl.     Publication Date:  1992  
Date Detail:
Created Date:  1993-01-15     Completed Date:  1993-01-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7801014     Medline TA:  Agents Actions Suppl     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  198-205     Citation Subset:  IM    
Kobe Research Projects on Thrombosis and Haemostasis, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Coagulation / drug effects
Bradykinin / biosynthesis
Disease Models, Animal
Disseminated Intravascular Coagulation / prevention & control
Endotoxins / toxicity
Fibrinogen / metabolism
Kallikreins / antagonists & inhibitors*
Kaolin / pharmacology
Partial Thromboplastin Time
Phenylalanine / analogs & derivatives*,  pharmacology
Tranexamic Acid / analogs & derivatives*,  pharmacology
Reg. No./Substance:
0/Endotoxins; 1197-18-8/Tranexamic Acid; 128837-71-8/PKSI 527; 1332-58-7/Kaolin; 58-82-2/Bradykinin; 63-91-2/Phenylalanine; 9001-32-5/Fibrinogen; EC 3.4.21.-/Kallikreins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Inhibition of glandular and plasma kallikrein by benzamidine derivatives.
Next Document:  Studies on the design of orally active peptide analogues.